Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass

Abstract

Introduction:

A high-pressure excursion (HPE) is a sudden increase in oxygenator inlet pressure during cardiopulmonary bypass (CPB). The aims of this study were to identify factors associated with HPE, to describe a treatment protocol utilizing epoprostenol in severe cases, and to assess early outcome in HPE patients.

Methods:

Patients who underwent cardiac surgery with cardiopulmonary bypass at Sahlgrenska University Hospital 2016–2018 were included in a retrospective observational study. Pre- and post-operative data collected from electronic health records, local databases, and registries were compared between HPE and non-HPE patients. Factors associated with HPE were identified with logistic regression models.

Results:

In total, 2024 patients were analyzed, and 37 (1.8%) developed HPE. Large body surface area (adjusted Odds Ratio (aOR): 1.43 per 0.1 m²; 95% confidence interval (CI): 1.16–1.76, p < 0.001), higher hematocrit during CPB (aOR: 1.20 per 1%; (1.09–1.33), p < 0.001), acute surgery (aOR: 2.98; (1.26–6.62), p = 0.018), and previous stroke (aOR: 2.93; (1.03–7.20), p = 0.027) were independently associated with HPE. HPE was treated with hemodilution (n = 29, 78.4%), and/or extra heparin (n = 23, 62.2%), and/or epoprostenol (n = 12, 32.4%). No oxygenator change-out was necessary. While there was no significant difference in 30-day mortality (2.7% vs 3.2%, p = 1.0), HPE was associated with a higher perioperative stroke rate (8.1% vs 1.8%, aOR 5.09 (1.17–15.57), p = 0.011).

Conclusions:

Large body surface area, high hematocrit during CPB, previous stroke and acute surgery were independently associated with HPE. A treatment protocol including epoprostenol appears to be a safe option. Perioperative stroke rate was increased in HPE patients.

Keywords

cardiopulmonary bypass oxygenator thrombosis epoprostenol prostaglandin oxygenator emergency change high pressure excursion

Get full access to this article

View all access options for this article.

References

Myers

Weighell

McCloskey

, et al. A multicenter investigation into the occurrence of high-pressure excursions. J Extra Corpor Technol 2003; 35: 127–132.

Fisher

Baker

Buffin

, et al. Normal and abnormal trans-oxygenator pressure gradients during cardiopulmonary bypass. Perfusion 2003; 18: 25–30.

Wahba

Philipp

Behr

, et al. Heparin-coated equipment reduces the risk of oxygenator failure. Ann Thorac Surg 1998; 65: 1310–1312.

Svenmarker

Häggmark

Jansson

, et al. The relative safety of an oxygenator. Perfusion 1997; 12: 289–292.

Sera

Primum non nocere: patient safety in cardiopulmonary bypass. In: Gravlee

(ed.) Cardiopulmonary bypass: principles and practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp.589–607.

Schaadt

Oxygenator thrombosis: an international phenomenon. Perfusion 1999; 14: 425–435.

Blombäck

Kronlund

Aberg

, et al. Pathologic fibrin formation and cold-induced clotting of membrane oxygenators during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1995; 9: 34–43.

Williams

Fatah

Ivert

, et al. The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718–725.

Wendel

Philipp

Weber

, et al. Oxygenator thrombosis: worst case after development of an abnormal pressure gradient-incidence and pathway. Perfusion 2001; 16: 271–278.

10.

Moncada

Gryglewski

Bunting

, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665.

11.

Thunberg

Gaitan

Grewal

, et al. Pulmonary hypertension in patients undergoing cardiac surgery: pathophysiology, perioperative management, and outcomes. J Cardiothorac Vasc Anesth 2013; 27: 551–572.

12.

Moitra

Sladen

. Cardiopulmonary bypass and the lung. In: Gravlee

(ed.) Cardiopulmonary bypass: principles and practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp.311–320.

13.

Tamburrelli

Crescente

Izzi

, et al. Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thromb Res 2011; 128: 446–451.

14.

Hjärpe

Reinsfelt

Epoprostenol for the treatment of increasing oxygenator pressure drop during cardiopulmonary bypass. A case report. Perfusion 2018; 33: 228–231.

15.

Hessel

II . Circuitry and cannulation techniques. In: Gravlee

(ed.) Cardiopulmonary bypass: principles and practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp.63–113.

16.

R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2020.

17.

RStudio Team. RStudio: integrated development environment for R. Boston, MA: RStudio, PBC, 2020.

18.

Brambilla

Camera

Colnago

, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 2008; 28: 947–953.

19.

Schrottmaier

Mussbacher

Salzmann

, et al. Platelet-leukocyte interplay during vascular disease. Atherosclerosis 2020; 307: 109–120.

20.

Aarts

van den Broek

Prins

, et al. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis 1988; 8: 819–824.

21.

Rana

Westein

Niego

, et al. Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities. Front Cardiovasc Med 2019; 6: 141.

22.

DiSesa

Huval

Lelcuk

, et al. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 1984; 38: 514–519.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB